New Approaches To Mechanism, Modality, And Manufacturing Challenges For EVs

In this segment of Cell & Gene Live, Redefining CGTs with Exosomes and EVs, Aegle Therapeutics’ Dr. Gloria Matthews explains the use of native, unmodified mesenchymal stem cell-derived extracellular vesicles (EVs) to deliver a complex regenerative payload that fuses quickly with local cells, offering a distinct advantage over small molecules and traditional biologics, which typically lack this targeted, one-time delivery mechanism. Unlike engineered EVs designed to carry specific genes or proteins, Aegle’s approach taps into the natural reparative and immunomodulatory cargo of EVs to stimulate healing in a more holistic way. While this strategy shows promise, the company acknowledges significant challenges in scaling production and ensuring consistency for broader clinical use, especially for systemic indications requiring repeated dosing.